Clinically, BC can be divided into distinct subtypes based on hormone receptor status: Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER-2+), and triple-negative breast cancers (TNBC) [9,10]. This evidence concerns the gene ERBB2 and breast cancer.